Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017160 (gastroenteritis)
 11,398 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

THE FLUORESCENT ANTIBODY (FA) TEST FOR THE DIAGNOSIS OF FIELD OUTBREAKS OF TRANSMISSIBLE GASTROENTERITIS (TGE) IN BABY PIGS WAS COMPARED TO OTHER AVAILABLE MEANS INCLUDING: virus isolation by inoculation of test pigs, intestinal lesions especially villous atrophy, and clinical observations. Immunofluorescent tests were done on frozen sections of the small intestine and it was possible to make a specific diagnosis within two hours after collecting samples. The results obtained with the FA test compared favorably with virus isolation from infected tissues. It was considered a more advantageous procedure as long as infected pigs were in a relatively early phase of the disease. Because of the variability of the lesions as related to the stage of infection, pathologic diagnoses were less satisfactory. Field diagnoses made on the basis of clinical signs were least reliable.
 ...
PMID:Diagnosis of transmissible gastroenteritis in pigs by means of immunofluorescence. 423 88

In the past centuries, different preparations of marijuana have been used for the treatment of gastrointestinal (GI) disorders, such as GI pain, gastroenteritis and diarrhea. Delta9-tetrahydrocannabinol (THC; the active component of marijuana), as well as endogenous and synthetic cannabinoids, exert their biological functions on the gastrointestinal tract by activating two types of cannabinoid receptors, cannabinoid type 1 receptor (CB1 receptor) and cannabinoid type 2 receptor (CB2 receptor). While CB1 receptors are located in the enteric nervous system and in sensory terminals of vagal and spinal neurons and regulate neurotransmitter release, CB2 receptors are mostly distributed in the immune system, with a role presently still difficult to establish. Under pathophysiological conditions, the endocannabinoid system conveys protection to the GI tract, eg from inflammation and abnormally high gastric and enteric secretion. For such protective activities, the endocannabinoid system may represent a new promising therapeutic target against different GI disorders, including frankly inflammatory bowel diseases (eg, Crohn's disease), functional bowel diseases (eg, irritable bowel syndrome), and secretion- and motility-related disorders.
 ...
PMID:Endocannabinoids and the gastrointestinal tract. 1675 8